I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently Amended) An oral dosage form, comprising
an orally therapeutically effective ~~amount~~ dose of an opioid agonist, and naltrexone or a pharmaceutically acceptable salt thereof
~~an opioid antagonist~~, ~~the ratio of opioid antagonist~~ the dosage form having a ratio of naltrexone or pharmaceutically acceptable salt thereof to opioid agonist ~~providing~~ that provides a combination product which is analgesically effective when the combination is administered orally, but which is aversive in physically dependent human subjects when administered at the same dose or at a higher dose than the ~~usually prescribed dose of the opioid agonist~~ therapeutically effective dose.

2. (Currently Amended) The oral dosage form of claim 1, wherein the amount of ~~antagonist~~ naltrexone or pharmaceutically acceptable salt thereof included in the oral dosage form causes an aversive experience in a physically dependent addict taking about 2-3 times the usually prescribed dose of the opioid.

3. (Currently Amended) The oral dosage form of claim 1, wherein the opioid agonist is hydrocodone or a pharmaceutically acceptable salt thereof ~~and the antagonist is naltrexone~~.

4. (Original) The oral dosage form of claim 3, wherein the ratio of naltrexone to hydrocodone is from about 0.03:1 to about 0.27:1.

5. (Original) The oral dosage form of claim 3, wherein the ratio of naltrexone to hydrocodone is from about 0.05:1 to about 0.20:1.

6. (Original) The oral dosage form of claim 1, wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, hydrocodone, oxycodone, codeine, levorphanol, meperidine, methadone, and mixtures thereof.

7. (Original) The oral dosage form of claim 1, further comprising an additional non-opioid drug selected from the group consisting of an NSAID, a COX-2 inhibitor, acetaminophen, aspirin, an NMDA receptor antagonist, a drug that blocks a major intracellular consequence of NMDA-receptor activation, an antitussive, an expectorant, a decongestant, an antihistamine and mixtures thereof.

8. (Original) The oral dosage form of claim 1, further comprising one or more pharmaceutically acceptable inert excipients.

9. (Cancelled)

10. (Currently Amended) The oral dosage form of claim ~~6~~ 1, wherein said ~~opioid antagonist is~~ naltrexone or pharmaceutically acceptable salt thereof is naltrexone hydrochloride.

11. (Original) The oral dosage form of claim 1, further comprising a sustained release carrier which imparts sustained release properties to said opioid agonist.

12. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is oxycodone or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to oxycodone is from about 0.037:1 to about 0.296:1.

13. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is codeine or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to codeine is from about 0.005:1 to about 0.044:1.

14. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is hydromorphone or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to hydromorphone is from about 0.148:1 to about 1.185:1.

15. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is levorphanol or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to levorphanol is from about 0.278:1 to about 2.222:1.

16. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is meperidine or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to meperidine is from about 0.0037:1 to about 0.0296:1.

17. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is methadone or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to methadone is from about 0.056:1 to about 0.444:1.

18. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is morphine or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to morphine is from about 0.018:1 to about 0.148:1.

19. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is oxycodone or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to oxycodone is from about 0.056:1 to about 0.222:1.

20. (Currently Amended) The oral dosage form of claim 1, wherein ~~said opioid antagonist is naltrexone and~~ said opioid agonist is codeine or a pharmaceutically acceptable salt thereof, ~~wherein~~ and the ratio of naltrexone to codeine is from about 0.0083:1 to about 0.033:1.

Claims 21 - 35 (Cancelled).